Developmental Therapeutics Program

摘要 发展治疗学（DT）计划的目标是将基础科学发现转化为临床应用。 适用于所有年龄段的患者，改善集水区患者的生活质量， 超越。成员开发，测试和研究新的治疗方法在成人和儿童患者的固体和 血液恶性肿瘤和领导合作，多机构的倡议，以建立新的治疗 范例DT计划通过改善获得护理的机会和培训下一个 癌症研究人员的一代，专注于指导早期职业教师。DT计划增加了两个 作为先前审查的结果，重点是：1）通过开发 IIT孵化器，并在早期试验和特定疾病组中优先考虑IIT，特别是那些已开发的 被辅导的成员。因此，干预治疗IIT的应计费用从2016年的47增加到2017年的3倍。 2020年140。和2）增强临床前异种移植物开发以促进免疫生物学/免疫疗法 的发现DT资助的试点赠款生产孤儿疾病PDX，结肠直肠癌的人源化模型（HM） 癌症和黑色素瘤中的自体HM。委员会共有78名成员，分别代表18个部门和4所学校， 拥有320万美元的NCI，200万美元的其他NIH和280万美元的其他同行评审资金，同行评审资金增加了50%， 审查研究经费从2016年的540万美元增加到2020年的800万美元。自2016年以来，DT会员注册2688人 641例受试者参与了干预治疗试验，增加了29%。DT成员发布了1000份同行评审 癌症相关论文，其中48%为合作论文（15%为内部论文; 17%为内部论文; 16%为两者），24%为期刊论文 如果大于10。其中47%（47%）代表与其他NCI指定的癌症合作 中心.科罗拉多大学癌症中心（UCCC）教育活动、培训/职业发展 活动和共享资源（SR）支持是DT资助试点赠款优先事项的基础， 强调“本土”疗法和将发现应用于临床。这些投资导致 成功的计划项目合作和跨UCCC的多PI资助。DT继续扩张 UCCC内部以及与包括科罗拉多大学博尔德分校在内的主要合作伙伴的多方利益相关者伙伴关系 (UCB)、科罗拉多州立大学（CSU）、科罗拉多大学医院（UCH）、科罗拉多儿童医院 （CHCO）和退伍军人管理局（VA）。UCH、CHCO和VA利用统一和共享的机构 审查委员会，使一个强大的合规系统能够应用DT项目发现并使患者受益， 集水区，同时简化病人的通道。DT计划继续专注于推进 通过支持试点项目，使用NIH研究评估， 商业化中心（REACH）计划，支持初创企业，并鼓励SBIR应用。最后， DT计划促进了战略招聘， 成人和伴侣动物模型，影响整个癌症谱的患者护理。

ABSTRACT The goal of the Developmental Therapeutics (DT) program is to translate basic scientific discovery to clinical application to benefit patients of all ages, improving the quality of life for patients in the catchment area and beyond. Members develop, test, and institute novel therapies in adult and pediatric patients with solid and hematologic malignancies and lead collaborative, multi-institutional initiatives to establish new treatment paradigms. The DT program serves the catchment area by improving access to care, and training the next generation of cancer researchers, focusing on mentoring early-career faculty. The DT program had two added points of focus as a result of the prior review: 1) enhancing investigator-initiated trials (IITs) by developing the IIT incubator and prioritizing IITs in early-phase trial and disease-specific groups, particularly those developed by mentored members. As a result, accruals to intervention treatment IITs increased 3-fold from 47 in 2016 to 140 in 2020. And 2) enhancing preclinical xenograft development to foster immunobiology/immunotherapy discovery. DT funded pilot grants producing orphan disease PDXs, humanized models (HM) for colorectal cancer, and an autologous HM in melanoma. With 78 members representing 18 departments and 4 schools, DT holds $3.2M in NCI, $2.0M in other NIH, and $2.8M in other peer-reviewed funding, a 50% increase in peer- reviewed research funding from $5.4M in 2016 to $8.0M in 2020. Since 2016, DT members enrolled 2688 subjects to 641 intervention treatment trials, an increase of 29%. DT members published 1000 peer-reviewed cancer-related papers, of which 48% were collaborative (15% inter-; 17% intra-; 16% both) and 24% in journals with an IF>10. Forty-seven percent (47%) of these represent collaborations with other NCI-designated cancer centers. University of Colorado Cancer Center (UCCC) educational activities, training/career enhancement activities, and shared resources (SRs) support are foundational to the DT's priorities of funding pilot grants that emphasize “homegrown” therapies and bench-to-bedside application of discoveries. These investments led to successful program project collaborations and multiple-PI funding across the UCCC. DT continues to expand multi-stakeholder partnerships within UCCC and with key partners, including the University of Colorado Boulder (UCB), Colorado State University (CSU), University of Colorado Hospital (UCH), Children's Hospital Colorado (CHCO), and the Veterans Administration (VA). UCH, CHCO, and the VA utilize a unified and shared Institutional Review Board, enabling a robust and compliant system to apply DT program discoveries and benefit patients in the catchment area, while streamlining access for patients. The DT program continues to focus on advancing novel compounds developed within UCCC by supporting pilot projects, using the NIH Research Evaluation and Commercialization Hubs (REACH) program, supporting start-ups, and encouraging SBIR applications. Lastly, the DT program has fostered strategic recruitments to strengthen its membership to better integrate pediatric, adult, and companion animal models, impacting patient care across the spectrum of cancer.